Can Horizon Therapeutics Public Limited Company (HZNP) stock recover despite sales dropping?

The price of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) shares last traded on Wall Street rose 0.40% to $112.60.

Based on available information, 7 analysts follow Horizon Therapeutics Public Limited Company (NASDAQ:HZNP). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $116.50 and a low of $116.50, we find $116.50. Given the previous closing price of $112.15, this indicates a potential upside of 3.88 percent. HZNP stock price is now 9.44% away from the 50-day moving average and 7.43% away from the 200-day moving average. The market capitalization of the company currently stands at $25.71B.

Among analysts, 6 rate the stock a hold while 1 rate it a buy. Brokers who have rated the stock have averaged $116.50 as their price target over the next twelve months.

With the price target of $74, H.C. Wainwright recently initiated with Neutral rating for Horizon Therapeutics Public Limited Company (NASDAQ: HZNP).

In other news, Pasternak Andy, EVP, Chief Strategy Officer sold 27,129 shares of the company’s stock on Jan 17. The stock was sold for $3,066,323 at an average price of $113.03. Upon completion of the transaction, the EVP, Chief Strategy Officer now directly owns 56,338 shares in the company, valued at $6.34 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 13, EVP, Chief Financial Officer Cox Aaron sold 36,148 shares of the business’s stock. A total of $4,090,847 was realized by selling the stock at an average price of $113.17. This leaves the insider owning 277 shares of the company worth $31190.2. Insiders disposed of 507,379 shares of company stock worth roughly $57.13 million over the past 1 year. A total of 1.18% of the company’s stock is owned by insiders.

There have been several recent changes in the stakes of large investors in HZNP stock. A new stake in Horizon Therapeutics Public Limited Company shares was purchased by SEGANTII CAPITAL MANAGEMENT LTD during the first quarter worth $122,171,000. RTW INVESTMENTS, LP invested $112,600,000 in shares of HZNP during the first quarter. In the first quarter, ABRAMS CAPITAL MANAGEMENT, L.P. acquired a new stake in Horizon Therapeutics Public Limited Company valued at approximately $100,326,000. THIRD POINT LLC acquired a new stake in HZNP for approximately $56,300,000. EAGLE ASSET MANAGEMENT INC purchased a new stake in HZNP valued at around $53,335,000 in the second quarter. In total, there are 814 active investors with 95.80% ownership of the company’s stock.

A candlestick chart of Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) showed a price of $112.16 on Tuesday morning. During the past 12 months, Horizon Therapeutics Public Limited Company has had a low of $57.84 and a high of $113.83. As of last week, the company has a debt-to-equity ratio of 0.48, a current ratio of 4.30, and a quick ratio of 4.10. According to the stock market information, the enterprise value for the company is $25.74B, which is based on a 60.18 price-to-earnings ratio, a 12.04 price-to-earnings-growth ratio, and a beta of 1.03. The fifty day moving average price for HZNP is $103.11 and a two-hundred day moving average price translates $105.00 for the stock.

The latest earnings results from Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) was released for Jun, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $1.2, beating analysts’ expectations of $1.03 by 0.17. This compares to $0.26 EPS in the same period last year. The net profit margin was 12.00% and return on equity was 8.50% for HZNP. The company reported revenue of $944.96 million for the quarter, compared to $876.41 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 7.82 percent. For the current quarter, analysts expect HZNP to generate $1B in revenue.

Horizon Therapeutics Public Limited Company(HZNP) Company Profile

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.